MediWound (NASDAQ:MDWD) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of MediWound (NASDAQ:MDWD) in a report published on Thursday morning,Benzinga reports. HC Wainwright currently has a $25.00 price objective on the biopharmaceutical company’s stock.

Separately, Craig Hallum initiated coverage on MediWound in a research report on Friday, February 28th. They set a “buy” rating and a $39.00 price objective for the company.

MediWound Stock Down 6.7 %

Shares of MDWD stock opened at $17.05 on Thursday. MediWound has a fifty-two week low of $12.78 and a fifty-two week high of $24.00. The stock has a market cap of $183.90 million, a P/E ratio of -5.88 and a beta of 0.82. The business has a fifty day simple moving average of $18.18 and a 200-day simple moving average of $17.60.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings results on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.23. MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. The business had revenue of $5.84 million during the quarter, compared to analysts’ expectations of $5.79 million. During the same quarter last year, the business posted ($0.19) earnings per share. On average, sell-side analysts anticipate that MediWound will post -2.66 earnings per share for the current year.

Hedge Funds Weigh In On MediWound

Several hedge funds and other institutional investors have recently modified their holdings of the company. Rhumbline Advisers lifted its stake in shares of MediWound by 7.3% in the 4th quarter. Rhumbline Advisers now owns 10,835 shares of the biopharmaceutical company’s stock valued at $193,000 after purchasing an additional 739 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in shares of MediWound by 154.1% in the 4th quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 1,162 shares in the last quarter. Barclays PLC lifted its stake in shares of MediWound by 11.2% in the 4th quarter. Barclays PLC now owns 12,412 shares of the biopharmaceutical company’s stock valued at $221,000 after purchasing an additional 1,249 shares in the last quarter. R Squared Ltd purchased a new stake in shares of MediWound during the 4th quarter valued at about $32,000. Finally, Bank of America Corp DE raised its holdings in shares of MediWound by 38.0% during the 4th quarter. Bank of America Corp DE now owns 7,915 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 2,178 shares during the period. 46.83% of the stock is owned by institutional investors and hedge funds.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.